<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39375604</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Associations between clinical data, vaccination status, antibody responses, and post-COVID-19 symptoms in Thais infected with SARS-CoV-2 Delta and Omicron variants: a 1-year follow-up study.</ArticleTitle><Pagination><StartPage>1116</StartPage><MedlinePgn>1116</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09999-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), led to a global pandemic from 2020. In Thailand, five waves of outbreaks were recorded, with the fourth and fifth waves driven by the Delta and Omicron variants, resulting in over 20,000 new confirmed cases daily at their peaks.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study investigated the associations between clinical symptoms, vaccination status, antibody responses, and post-COVID-19 sequelae in COVID-19 patients. Plasma samples and clinical data were collected from participants admitted to hospitals in Thailand between July 2021 and August 2022, with follow-ups conducted for one year. The study included 110 participants infected with either the Delta (n = 46) or Omicron (n = 64) variants. Virus genotypes were confirmed by RT-PCR of nasal swab RNA and partial nucleotide sequencing of the S gene. IgG and IgA antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 Delta and Omicron variants were measured in plasma samples using ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pneumonia was found to be associated with Delta variant infections, while sore throat, congestion or runny nose, and headache were linked to Omicron infections. Vaccination with fewer than two doses and diabetes mellitus were significantly associated with higher disease severity. Specific IgG and IgA antibodies against the RBD of the Delta variant generally rose by day 14 and were maintained for up to two months, whereas the pattern of antibody response to the Omicron variant was less clear. Antibody risings were found to be positively associated with pneumonia, certain underlying conditions (obesity, hypertension, dyslipidemia, and diabetes mellitus), and age ≥ 60 years. Delta variant infections were associated with forgetfulness, hair loss, and headache during the 1-year post-infection period. Females were more likely to experience hair loss, forgetfulness, and joint pain, while older age was associated with joint pain.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study enhances our understanding of SARS-CoV-2 infections in Thais, particularly concerning the Delta and Omicron variants. The findings can inform public health planning and response strategies for future outbreaks of SARS-CoV-2 or other emerging viral diseases.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khongsiri</LastName><ForeName>Wathusiri</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poolchanuan</LastName><ForeName>Prapassorn</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dulsuk</LastName><ForeName>Adul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thippornchai</LastName><ForeName>Narin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phunpang</LastName><ForeName>Rungnapa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Runcharoen</LastName><ForeName>Chakkaphan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Medical Genomics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boonprakob</LastName><ForeName>Thitiya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Prachatipat Hospital, Pathum Thani, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemtong</LastName><ForeName>Onura</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Prachatipat Hospital, Pathum Thani, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowplijit</LastName><ForeName>Suchada</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vichaivej International Hospital, Samut Sakhon, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuapaknam</LastName><ForeName>Vachara</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Vichaivej International Hospital, Samut Sakhon, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siripoon</LastName><ForeName>Tanaya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piyaphanee</LastName><ForeName>Watcharapong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thai Travel Clinic, Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luvira</LastName><ForeName>Viravarn</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotejanaprasert</LastName><ForeName>Chawarat</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leaungwutiwong</LastName><ForeName>Pornsawan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chantratita</LastName><ForeName>Wasun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Medical Genomics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chantratita</LastName><ForeName>Narisara</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosoltanapiwat</LastName><ForeName>Nathamon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand. nathamon.kos@mahidol.ac.th.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N" Type="Geographic">Thailand</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody response</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">ELISA</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Thailand</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375604</ArticleId><ArticleId IdType="pmc">PMC11460119</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09999-2</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09999-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bakhshandeh B, Jahanafrooz Z, Abbasi A, Goli MB, Sadeghi M, Mottaqi MS, et al. Mutations in SARS-CoV-2; consequences in structure, function, and pathogenicity of the virus. Microb Pathog. 2021;154:104831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955574</ArticleId><ArticleId IdType="pubmed">33727169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Wang W, Yuan Z, Jia R, Zhao Z, Xu X, et al. A study on antigenicity and receptor-binding ability of fragment 450–650 of the spike protein of SARS coronavirus. Virology. 2007;359:362–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103343</ArticleId><ArticleId IdType="pubmed">17055551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98:115094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260568</ArticleId><ArticleId IdType="pubmed">32623267</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan BS, Nambiar V. COVID-19: an insight into SARS-CoV-2 pandemic originated at Wuhan city in Hubei Province of China. J Infect Dis Epidemiol. 2020;6:146.</Citation></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Triukose S, Nitinawarat S, Satian P, Somboonsavatdee A, Chotikarn P, Thammasanya T, et al. Effects of public health interventions on the epidemiological spread during the first wave of the COVID-19 outbreak in Thailand. PLoS ONE. 2021;16:e0246274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894963</ArticleId><ArticleId IdType="pubmed">33606734</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report – 22. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf. Accessed 23 May 2024.</Citation></Reference><Reference><Citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19–11. March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 23 May 2024.</Citation></Reference><Reference><Citation>World Health Organization. WHO Thailand situation report – 266. https://www.who.int/thailand/news/detail/05-07-2023-the-situation-report-on-covid19. Accessed 23 May 2024.</Citation></Reference><Reference><Citation>World Health Organization. COVID-19 - WHO Thailand Situation Reports (Archive #1 - #100). https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports-(archive). Accessed 23 May 2024.</Citation></Reference><Reference><Citation>Rajatanavin N, Tuangratananon T, Suphanchaimat R, Tangcharoensathien V. Responding to the COVID-19 second wave in Thailand by diversifying and adapting lessons from the first wave. BMJ Glob Health. 2021;6:e006178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8295022</ArticleId><ArticleId IdType="pubmed">34285042</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. COVID-19 - WHO Thailand Situation Reports (Archive #101 - #254). https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports. Accessed 23 May 2024.</Citation></Reference><Reference><Citation>Suphanchaimat R, Teekasap P, Nittayasoot N, Phaiyarom M, Cetthakrikul N. Forecasted trends of the new COVID-19 epidemic due to the Omicron variant in Thailand, 2022. Vaccines (Basel). 2022;10:1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320113</ArticleId><ArticleId IdType="pubmed">35891188</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Thailand situation report – 157. https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports. Accessed 23 May 2024.</Citation></Reference><Reference><Citation>World Health Organization. WHO Thailand situation report – 187. https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports. Accessed 23 May 2024.</Citation></Reference><Reference><Citation>World Health Organization. WHO Thailand situation report – 214. https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports. Accessed 23 May 2024.</Citation></Reference><Reference><Citation>Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, et al. Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020–2022. Arch Virol. 2023;168:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9807426</ArticleId><ArticleId IdType="pubmed">36593392</ArticleId></ArticleIdList></Reference><Reference><Citation>Salles TS, Cavalcanti AC, da Costa FB, Dias VZ, de Souza LM, de Meneses MDF, et al. Genomic surveillance of SARS-CoV-2 spike gene by sanger sequencing. PLoS ONE. 2022;17:e0262170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8775319</ArticleId><ArticleId IdType="pubmed">35051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Panthan B, Kochakarn T, Jiaranai P, Runcharoen C, Sensorn I, Charoenyingwattana A, et al. Identification of SARS-CoV-2 lineages using a cost-effective MassARRAY®system. Southeast Asian J Trop Med Public Health. 2022;53:513–29.</Citation></Reference><Reference><Citation>Tandhavanant S, Koosakunirand S, Kaewarpai T, Piyaphanee W, Leaungwutiwong P, Luvira V, et al. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE. 2021;16:e0255796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8354433</ArticleId><ArticleId IdType="pubmed">34375345</ArticleId></ArticleIdList></Reference><Reference><Citation>Petcharat S, Supataragul A, Hirunpatrawong P, Torvorapanit P, Klungthong C, Chinnawirotpisan P et al. High transmission rates of early Omicron subvariant BA.2 in Bangkok, Thailand. Adv Virol. 2023; 2023: 4940767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10719011</ArticleId><ArticleId IdType="pubmed">38094619</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/. Accessed 23 May 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, COVID-19 Genomics UK Consortium, Peacock SJ, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Yang S, Wang L, Zhou Y, Xin Y, Li H, et al. Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China. Virol Sin. 2022;37:704–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9357284</ArticleId><ArticleId IdType="pubmed">35948265</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Liu X, Li L, Hu X, Cui G, Sun R, et al. Comparison of clinical characteristics between SARS-CoV-2 Omicron variant and Delta variant infections in China. Front Med (Lausanne). 2022;9:944909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9597612</ArticleId><ArticleId IdType="pubmed">36313994</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers C, Zacher B, Ullrich A, Huska M, Fuchs S, Buda S, et al. SARS-CoV-2 omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Euro Surveill. 2022;27:2200396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9164675</ArticleId><ArticleId IdType="pubmed">35656831</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A detailed overview of SARS-CoV-2 Omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses. 2023;15:167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9866114</ArticleId><ArticleId IdType="pubmed">36680207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Moazzami B, Chaichian S, Kasaeian A, Djalalinia S, Akhlaghdoust M, Eslami M, et al. Metabolic risk factors and risk of Covid-19: a systematic review and meta-analysis. PLoS ONE. 2020;15:e0243600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737901</ArticleId><ArticleId IdType="pubmed">33320875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Di. 2020;30:1236–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7258796</ArticleId><ArticleId IdType="pubmed">32571616</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallus S, Scala M, Possenti I, Jarach CM, Clancy L, Fernandez E, et al. The role of smoking in COVID-19 progression: a comprehensive meta-analysis. Eur Respir Rev. 2023;32:220191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10032583</ArticleId><ArticleId IdType="pubmed">36889786</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med. 2023;29:358–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9974584</ArticleId><ArticleId IdType="pubmed">36593393</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022;29:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9569411</ArticleId><ArticleId IdType="pubmed">36243868</ArticleId></ArticleIdList></Reference><Reference><Citation>Poolchanuan P, Matsee W, Sengyee S, Siripoon T, Dulsuk A, Phunpang R, et al. Dynamics of different classes and subclasses of antibody responses to severe acute respiratory syndrome coronavirus 2 variants after Coronavirus Disease 2019 and CoronaVac vaccination in Thailand. mSphere. 2023;8:e0046522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9942573</ArticleId><ArticleId IdType="pubmed">36688637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Barrett J, He X. Immune imprinting and implications for COVID-19. Vaccines (Basel). 2023;11:875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10142218</ArticleId><ArticleId IdType="pubmed">37112787</ArticleId></ArticleIdList></Reference><Reference><Citation>Linderman SL, Lai L, Bocangel Gamarra EL, Lau MS, Edupuganti S, Surie D, et al. Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection. J Clin Invest. 2022;132:e164303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711871</ArticleId><ArticleId IdType="pubmed">36256473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bormann M, Brochhagen L, Alt M, Otte M, Thümmler L, van de Sand L, et al. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5. Front Immunol. 2023;14:1150667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10372796</ArticleId><ArticleId IdType="pubmed">37520539</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wang J, Xu X, Liao G, Chen Y, Hu CH. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020;9:1269–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448841</ArticleId><ArticleId IdType="pubmed">32515684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17:773–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7331804</ArticleId><ArticleId IdType="pubmed">32467617</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Jia T, Chen J, Zeng S, Qiu Z, Wu S, et al. The characterization of disease severity associated IgG subclasses response in COVID-19 patients. Front Immunol. 2021;12:632814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7982848</ArticleId><ArticleId IdType="pubmed">33763078</ArticleId></ArticleIdList></Reference><Reference><Citation>Chansaenroj J, Yorsaeng R, Puenpa J, Wanlapakorn N, Chirathaworn C, Sudhinaraset N, et al. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients. PLoS ONE. 2022;17:e0267102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022880</ArticleId><ArticleId IdType="pubmed">35446889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai B, Clarke K, Bauer DL, Moehling Geffel KK, Kupul S, Schratz LJ, et al. SARS-CoV-2 antibody response is associated with age and body mass index in convalescent outpatients. J Immunol. 2022;208:1711–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976825</ArticleId><ArticleId IdType="pubmed">35321882</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38:e3465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209952</ArticleId><ArticleId IdType="pubmed">33955644</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmosudigdo IS, Lim MA, Radi B, Henrina J, Yonas E, Vania R, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. Clin Med Insights Endocrinol Diabetes. 2021;14:1179551421990675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8842489</ArticleId><ArticleId IdType="pubmed">35173508</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Segade S, Camiña MF, Carnero A, Lorenzo MJ, Alban A, Quinteiro C, et al. High serum IgA concentrations in patients with diabetes mellitus: agewise distribution and relation to chronic complications. Clin Chem. 1996;42:1064–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8674189</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetti L, Chapy H, Nahass RG, Moore R, Wassef A, Adler D, Yurkow E, Kagan L. Relationship between body composition and serum immunoglobulin concentrations after administration of intravenous immune globulin–preclinical and clinical evidence. Pharmaceutics. 2023;15:510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9958704</ArticleId><ArticleId IdType="pubmed">36839832</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-de-Las-Peñas C, Notarte KI, Peligro PJ, Velasco JV, Ocampo MJ, Henry BM, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. 2022;14:2629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun MC, Singh AK, Roy P, Ravichandran M, Mandal S, Pal D, et al. Long COVID following Omicron wave in Eastern India-A retrospective cohort study. J Med Virol. 2023;95:e28214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9874641</ArticleId><ArticleId IdType="pubmed">36224705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernández-Aceituno A, García-Hernández A, Larumbe-Zabala E. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. Infect Dis Now. 2023;53:104688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9970656</ArticleId><ArticleId IdType="pubmed">36858287</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Emiroglu C, Dicle M, Ozagar SD, Gorpelioglu S, Aypak C. Evaluation of post-acute-COVID-19, and long-COVID symptoms with a questionnaire: within one year, a longitudinal study. North Clin Istanb. 2024;11:105–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11095331</ArticleId><ArticleId IdType="pubmed">38757107</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwa D, Monga A, Kumar N, Khullar G, Karmakar S, Khunger N. A cross-sectional study on post-coronavirus disease (COVID-19) hair loss at a tertiary care hospital. Dermatol Pract Concept. 2023;13:e2023263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10656157</ArticleId><ArticleId IdType="pubmed">37992388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>